Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 3

2(40.0%)

5Total

Phase 2(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04668352Phase 3Completed

A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly

Role: lead

NCT04409327Phase 2Terminated

Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes

Role: lead

NCT04584710Phase 2Active Not Recruiting

A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults

Role: lead

NCT04139915Phase 3Withdrawn

Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly

Role: lead

NCT03373903Phase 2Active Not Recruiting

Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly

Role: lead

All 5 trials loaded